FAQ on NanoViricides' NV-387 as a Potential Treatment for Measles Outbreaks

What is NV-387 and who is developing it?

NV-387 is a broad-spectrum antiviral drug candidate developed by NanoViricides, Inc., a clinical-stage company specializing in antiviral therapies using nanomedicine technology.

Why is NV-387 considered a potential treatment for measles?

NV-387 has shown effectiveness and safety in animal studies and completed a Phase I clinical trial with no adverse events, indicating strong tolerability in humans, at a time when measles cases are rising and there is no approved drug for measles.

How does NV-387 work?

NV-387 is based on NanoViricides’ nanoviricide technology, which uses host-mimetic nanomedicine to target and neutralize viruses, although the specific mechanism of action against measles is not detailed in the content.

What are the current statistics on measles outbreaks mentioned in the content?

As of 2025, the U.S. has reported 1,319 measles cases, surpassing the 2019 record, Canada has reported over 3,800 cases, and the WHO reported 127,350 cases in Europe in 2024, the highest since 1997.

What designations could NV-387 qualify for and what benefits do they offer?

NV-387 may qualify for Orphan Drug and Fast Track designations, which could accelerate its approval process and offer seven years of market exclusivity.

What other infections is NanoViricides planning to treat with NV-387?

NanoViricides plans to develop NV-387 as a treatment for RSV, COVID-19, Long COVID, influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections.

What is the next step for NV-387 in its development?

The company is currently focused on advancing NV-387 into Phase II human clinical trials.

Where can I find more information about NanoViricides and NV-387?

For more information, visit NanoViricides’ website at www.NanoViricides.com or view the full press release at https://ibn.fm/w2BR6.